Royal Philips announced on November 19 2025 that it will extend its partnership with Cortechs.ai, a leader in quantitative neuro‑imaging software, to embed the company’s NeuroQuant® analytics directly into Philips’ magnetic‑resonance (MR) systems. The extension will integrate NeuroQuant’s Alzheimer’s, multiple‑sclerosis, and brain‑tumor lesion‑quantification modules into Philips’ Smart Reading cloud platform, enabling clinicians to receive automated, zero‑click quantitative reports within the standard MR workflow.
The new integration will add objective, reproducible brain‑volume and lesion‑tracking metrics to Philips’ MRI suite. By delivering these metrics automatically, the partnership aims to accelerate diagnosis, improve consistency across sites, and increase throughput for neuro‑diagnostic studies. The move also addresses a growing demand for neuro‑imaging services, as 25 % of all MR procedures are brain scans and radiology departments face staff shortages that limit manual reporting capacity.
Philips’ AI strategy has focused on embedding machine‑learning tools into its imaging hardware. The Cortechs.ai partnership builds on earlier collaborations, such as the 2015 integration of quantitative brain‑volume analysis, and represents a deeper commitment to precision diagnostics. By leveraging Smart Reading’s cloud‑based analytics, Philips can offer a seamless, zero‑click reporting experience that reduces technologist and radiologist workload, aligns with industry trends toward AI‑assisted workflow, and positions Philips ahead of competitors such as GE Healthcare and Siemens Healthineers.
The partnership is expected to become available in the next 6‑24 months, pending clinical validation and regulatory clearance. While the integration is not yet commercial, its potential to improve diagnostic accuracy and operational efficiency could translate into higher utilization of Philips’ MRI platforms and strengthen its market position in the neuro‑diagnostics segment. The collaboration also signals Philips’ intent to capture a larger share of the growing AI‑driven imaging market, which is projected to expand as neurological conditions such as Alzheimer’s and multiple sclerosis become more prevalent.
Philips’ executive team highlighted the strategic importance of the partnership, noting that “embedding AI‑enabled analytics into our MR systems brings precision, reproducibility, and efficiency to neurological imaging, helping clinicians make faster, more confident decisions for patients living with complex brain conditions.” The statement underscores Philips’ focus on leveraging AI to address workforce shortages and meet the rising demand for advanced diagnostics.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.